Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome
Response to Bakris et al.
- Kristel J. O'Malley, PHARMD1,
- Marshall J. Bouldin, MD1 and
- Daniel M. Riche, PHARMD2
- 1University of Mississippi Medical Center, Jackson, Mississippi
- 2University of Mississippi School of Pharmacy, Jackson, Mississippi
- Address correspondence to Daniel M. Riche, PharmD, BCPS, Clinical Assistant Professor, University of Mississippi Medical Center, Department of Pharmacy Practice, Office Annex Building, WW128, 2500 North State St., Jackson, MS 39216. E-mail: driche{at}sop.umsmed.edu
We read with great interest the recent article by Bakris et al. (1). The authors reported that in patients with impaired glucose tolerance (IGT), the combination of losartan and hydrochlorothiazide resulted in an increased rate of new-onset diabetes when compared with trandolapril and verapamil. Indeed, we agree that thiazide diuretics have a history of producing adverse metabolic effects; however, we contend that losartan is an inappropriate angiotensin receptor blocker (ARB) choice. Losartan has inadequate peroxisome proliferator–activated receptor …
